Department of Medical Oncology, University of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey.
Department of General Surgery, University of Health Sciences, Umraniye Education and Research Hospital, Istanbul, Turkey.
J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
To compare the overall survival and progression-free survival of front-line cytoreductive surgery (CRs) ± hyperthermic intraperitoneal chemotherapy versus intensive systemic chemotherapy alone, in patients with isolated peritoneal carcinomatosis of colorectal origin.
Descriptive study.
Departments of Medical Oncology and Surgical Oncology in University of Health Sciences, Umraniye Education and Research Hospital, from January 2017 to January 2020.
Clinicopathological data of patients presented with isolated peritoneal carcinomatosis were categorised into two groups according to their treatment type as patients who received intensive systemic chemotherapy alone or underwent front-line CRS ± HIPEC. Overall and progression-free survival outcomes of the two approaches were quantified by survival analysis and compared with each other. The other collected variables were age, gender, performance status, tumor site and type of systemic chemotherapy.
Overall, 109 patients were included. The median progression-free survival of patients treated with cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy was 12 months; whereas, it was 9 months in those treated with intensive systemic chemotherapy alone (p=0.011). The median overall survival was estimated as 32 months in patients treated with cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy, compared with 23 months for those treated with systemic chemotherapy alone (p=0.715).
Although not translated into overall survival gain, extended progression-free survival, may give an advantage to cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy when used with intensive systemic chemotherapy in the individualised treatment of isolated peritoneal carcinomatosis of colorectal carcinoma. Key Words: Colorectal carcinoma, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Overall survival, Peritoneal carcinomatosis, Systemic chemotherapy.
比较一线细胞减灭术（CRs）±腹腔内热灌注化疗与单纯强化全身化疗治疗结直肠来源孤立性腹膜癌患者的总生存期和无进展生存期。
描述性研究。
2017 年 1 月至 2020 年 1 月，在健康科学大学 Umraniye 教育和研究医院肿瘤内科和肿瘤外科。
根据治疗方式将表现为孤立性腹膜癌患者的临床病理数据分为两组，一组患者接受单纯强化全身化疗，另一组患者行一线 CRs±HIPEC。通过生存分析量化两种方法的总生存期和无进展生存期，并进行相互比较。收集的其他变量包括年龄、性别、体能状态、肿瘤部位和全身化疗类型。
共纳入 109 例患者。接受细胞减灭术±腹腔内热灌注化疗的患者中位无进展生存期为 12 个月，而接受单纯强化全身化疗的患者为 9 个月（p=0.011）。接受细胞减灭术±腹腔内热灌注化疗的患者中位总生存期估计为 32 个月，而接受单纯全身化疗的患者为 23 个月（p=0.715）。
尽管在总体生存方面没有转化为获益，但在个体化治疗结直肠来源孤立性腹膜癌时，与单纯全身化疗相比，延长无进展生存期可能使细胞减灭术±腹腔内热灌注化疗具有优势。关键词：结直肠癌、细胞减灭术、腹腔内热灌注化疗、总生存期、腹膜癌、全身化疗。
